Skip to main content
SpringerLink
Log in

Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury

  • Inflammation
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

We investigated the effect of BAY u3405, a thromboxane A2 receptor antagonist in pentobarbital anaesthetized rats subjected to left main coronary artery ligation (1 h) followed by reperfusion (1 h; MI/R). Sham operated rats were used as controls (Sham MI/R). Survival rate, myocardial necrosis, myocardial myeloperoxidase activity (investigated as an index of leukocyte adhesion and accumulation) and serum creatine phosphokinase activity were studied. Ischaemia-reperfusion injury significantly reduced the survival rate (45%), caused a marked myocardial necrosis, increased serum creatine phosphokinase activity (Sham MI/R=26±10.2 U/ml; MI/R=213±19 U/ml) and produced a rise in myocardial myeloperoxidase activity in the area-at-risk and in the necrotic area (6.1±0.4 U×10−3/g tissue and 6.7±0.9 U×10−3/g of tissue, respectively).

The administration of BAY u3405 (30 and 60 mg/kg/i.v., 30 min before occlusion) significantly increased survival rate, lowered the area of myocardial necrosis, blunted the increase in serum creatine phosphokinase activity and reduced the increase in myeloperoxidase activity in both the area-at-risk and the necrotic area. Furthermore, the protective effect of BAY u3405 was dose-dependent.

These data are consistent with an involvement of TXA2 in myocardial ischaemia-reperfusion injury and suggest that BAY u3405 may represent a novel therapeutic approach to the treatment of acute ischaemia-reperfusion injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. E. F. Smith III, A. M. Lefer and J. B. Smith,Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can. J. Physiol. Pharmacol.58, 294–300 (1980).

    PubMed  Google Scholar 

  2. A. M. Lefer,Significance of lipid mediators in shock states. Circ. Shock27, 3–12 (1989).

    PubMed  Google Scholar 

  3. P. Walinsky, J. B. Smith and A. M. Lefer et al.,Thromboxane A 2 in acute myocardial infarction. Am. Heart J.108, 868–872 (1984).

    Article  PubMed  Google Scholar 

  4. S. Morooka, M. Kobayashi and T. Shimamoto,Experimental ischemic heart disease induced by thromboxane A 2 in rabbits. Jap. Circ. J.41, 1373–1379 (1978).

    Google Scholar 

  5. E. F. Smith III, A. M. Lefer and D. Aharony et al.,Carbocyclic thromboxane A 2 : Aggravation of myocardial ischemia by a new synthetic thromboxane analog. Prostaglandins21, 443–456 (1981).

    Article  PubMed  Google Scholar 

  6. S. E. Burke, G. DiCola and A. M. Lefer,Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A 2 synthesis inhibitor. J. Cardiovasc. Pharmacol.5, 842–847 (1983).

    PubMed  Google Scholar 

  7. B. M. Lucchesi,Modulation of leukocyte-mediated myocardial reperfusion injury. Annu. Rev. Physiol.52, 561 (1990).

    Article  PubMed  Google Scholar 

  8. P. M. Vanhoutte and D. S. Houston,Platelets, endothelium and vasopasm. Circulation72, 728–735 (1985).

    PubMed  Google Scholar 

  9. A. M. Lefer and H. Darius,A pharmacological approach to thromboxane receptor antagonism. Fed. Proc.46, 144–148 (1987).

    PubMed  Google Scholar 

  10. E. Perzborn, F. Seuter, V. B. Fiedler, U. Rosentreter and H. B. Shagen,Action of the novel selective Thromboxane antagonist (3R)-3(4-Fluorophenylsulfonamido)-1, 2. 3, 4-tetrahydro-9-carbozole-propanoic acid on vascular smooth muscle preparations. Arzneim Forsch/Drug Res.39(II), 1522–1525 (1989).

    Google Scholar 

  11. X. Norel, C. Labat, P. J. Gardiner and C. Brink,Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchila and pulmonary arterial muscle preparations Br. J. Pharmacol.104, 591–595 (1991).

    PubMed  Google Scholar 

  12. P. H. Rounding and V. B. Fiedler,Improved coronary thrombolysis by tissue-type plasminogen activator in the presence of BAY u3405. Eur. J. Pharmacol.198, 207–210 (1991).

    Article  PubMed  Google Scholar 

  13. H. P. Francis, S. J. Greenham, U. P. Patel, A. M. Thompson and P. J. Gardiner,BAY u3405 an antagonist of thromboxane A 2 and prostaglandin D 2 induced bronchoconstriction in the guinea-pig. Br. J. Pharmacol.104, 596–602 (1991).

    PubMed  Google Scholar 

  14. A. P. Caputi, F. Rossi, F. Carney and H. E. Brezenoff,Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats. J. Pharmacol. Exp. Ther.215, 309–316 (1980).

    PubMed  Google Scholar 

  15. M. A. Petty, J. Dow, J. M. Grisar and W. De Jong,Effect of a cardioselective α-tocopherol analogue on reperfusion injury in rats induced by myocardial ischemia. Eur. J. Pharmacol.192, 383–388 (1991).

    Article  PubMed  Google Scholar 

  16. S. B. Rosalki,An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med.69, 696–705 (1967).

    PubMed  Google Scholar 

  17. K. M. Mullane, R. Kraemer and B. Smith,Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into isochemic myocardium. J. Pharmacol. Meth.14, 157–167 (1985).

    Article  Google Scholar 

  18. A. M. Lefer, G. Johnson III, M. Xin-Liang, P. S. Tsao and G. R. Thomas,Cardioprotective and endothelial protective effects of [Ala-IL8] in a rabbit model of myocardial ischemia and reperfusion. Br. J. Pharmacol.103, 1153–1159 (1991).

    PubMed  Google Scholar 

  19. D. E. Griswold, L. M. Hillegass, D. E. Hill, J. W. Egan and E. F. Smith III,Method for quantification of myocardial infarction and inflammatroy cell infiltration in rat cardiac tissue. J. Pharmacol. Meth.20, 225–235 (1988).

    Article  Google Scholar 

  20. S. J. Coker, J. R. Parratt,AH 23848, a thromboxane receptor antagonist suppresses ischemic and reperfusion-induced arrhythmias in anesthetized greyhounds. Br. J. Pharmacol.86, 259–264 (1985).

    PubMed  Google Scholar 

  21. P. Braquet, L. Touqui, T. Y. Shen and G. G. Vargaftig,Perspectives in platelet-activating factor research. Pharmacol. Rev.39, 97–145 (1987).

    PubMed  Google Scholar 

  22. G. Feuerstein,Leukotrienes and the cardiovascular system. Prostaglandins27, 781–802 (1984).

    Article  PubMed  Google Scholar 

  23. J. M. McCord,Oxygen-derived free radicals in post ischemic tissue injury. New Engl. J. Med.312, 159–163 (1985).

    PubMed  Google Scholar 

  24. J. L. Mehta, W. W. Nichols and P. Mehta,Neutrophils as potential participants in acute myocardial ischemia: Relevance to reperfusion. J. Am. Coll. Cardiol.11, 1309–1316 (1988).

    PubMed  Google Scholar 

  25. J. L. Dinerman and J. L. Mehta,Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanisms and their clinical relevance. J. Am. Coll. Cardiol.16, 207–222 (1990).

    PubMed  Google Scholar 

  26. K. M. Mullane, J. A. Salmon and S. Moncada,Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to myocardial salvage by anti-inflammatory drugs. J. Pharmacol. Exp. Ther.510, 510–522 (1984).

    Google Scholar 

  27. R. Engler and J. W. Covell,Granulocytes cause reperfusion ventricular dysfunction after 15 minute ischemia in the dog. Circ. Res.61, 20–28 (1987).

    PubMed  Google Scholar 

  28. J. L. Romson, B. G. Hook, V. H. Rigot, M. A. Schork, D. P. Swanson and B. R. Lucchesi,The effect of ibuprofen on accumulation of indium-111-labeled platelets and leukocytes in experimental myocardial infarction. Circulation66, 1002–1011 (1982).

    PubMed  Google Scholar 

  29. F. Squadrito et al.,Protective effects of G-619, a dual thromboxane synthase inhibitor and thromboxane A 2 receptor antagonist, in splanchnic artery occlusion shock. J. Cardiovasc. Pharmacol.19, 115–119 (1992).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Messina, Milano, Italy

    A. Saitta (Institute of Pharmacology, Chair of Medical Therapeutics) & S. Oriti (Institute of Pharmacology, Chair of Medical Therapeutics)

  2. Garbagnate Milanese, BAYER S.P.A., Milano, Italy

    A. Faggiotto

  3. Institute of Pharmacology, School of Medicine, Piazza XX Settembre 4, 98122, Messina, Italy

    F. Squadrito MD.

Authors
  1. F. Squadrito MD.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ioculano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Altavilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Zingarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Canale
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. M. Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Saitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Oriti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Faggiotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. P. Caputi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Squadrito, F., Ioculano, M., Altavilla, D. et al. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury. Agents and Actions 39, 143–149 (1993). https://doi.org/10.1007/BF01998967

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01998967

Keywords

Search

Navigation